New Base Pharmaceuticals buys global rights to Horizon Pharmaceuticals' Imukin

The UK's New Base Pharmaceuticals Group has bought global rights to treatment for rare diseases from Horizon Pharmaceuticals for an unsealed amount.
Imukin (recombinant human interferon γ-1b) is currently licensed in 19 countries worldwide to reduce the frequency of severe infections in patients with chronic granuloma (CGD) and to treat severe malignant osteopathy (SMO).CGD is a set of heterogeneity genetic disorders in which certain cells of the immune system have difficulty forming the reactive oxygen compounds needed to kill certain ingested pathogens, which usually begin early in life and can lead to child death.
is a rare congenital disease caused by bone-breaking cells that can no longer absorb immature bones, characterized by frequent fractures, visual impairment and bone marrow failure. If left untreated, most patients die from repeated infections in the first decade of life.
as an auxiliary drug for CGD antimicrobial therapy as a macrophage stimulator and to reduce the frequency of serious infections in SMO patients.
said he intends to "reinvigorate" the treatment by working with healthcare professionals "to ensure that its benefits to patients are fully understood".
group also plans to make the drug available to those who need it through its global distribution network, he said.
" Imukin strengthens our commercial supply and represents a good strategic fit for our drug portfolio growth strategy, which focuses on products in the oncology and rare diseases sectors. Sean Chilton, the group's chief executive, commented on the move. (China Pharmaceutical 123 Network)